ArticleEuropean journal of preventive cardiology2024
Artificial intelligence electrocardiogram as a novel screening tool to detect a newly abnormal left ventricular ejection fraction after anthracycline-based cancer therapy.
Article in European journal of preventive cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- External validation of artificial intelligence-guided electrocardiogram (AI-ECG) in detecting asymptomatic left ventricular dysfunction: A systematic review and meta-analysis.American journal of preventive cardiology · 2027Article
- Risk-guided cardioprotection in cardio-oncology.Nature cardiovascular research · 2026Review
- Advances in the Interpretation of the Electrocardiogram by Artificial Intelligence.Diagnostics (Basel, Switzerland) · 2026Review
- Cardiotoxicity of Targeted Therapies in Hematologic Malignancies: From Molecular Mechanisms to Clinical Management.Current treatment options in oncology · 2026Review
- Review
- From data to decision: a clinical pipeline for wearable AI in early cardiotoxicity detection.Cardio-oncology (London, England) · 2026Review
- Diagnostics in cardio-oncology: a focus on anthracyclines.Heart failure reviews · 2026Review
- Artificial Intelligence and the Expanding Universe of Cardio-Oncology: Beyond Detection Toward Prediction and Prevention of Therapy-Related Cardiotoxicity-A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2026Review
- AI-ECG for Echocardiography Triage in Structural Heart Disease: Evidence, Implementation, and Future Directions.International journal of general medicine · 2026Review
- Chemotherapy-induced cardiotoxicity in breast cancer: mechanisms, diagnostic advances, and emerging protective strategies.American journal of physiology. Heart and circulatory physiology · 2025Review
- Artificial Intelligence-Enabled Electrocardiogram for the Detection and Management of Cancer Therapy-Related Cardiotoxicity.Cancer innovation · 2025Article
- Evolving Cardioprotective Strategies in Cardio-Oncology: A Narrative Review.Current cardiology reports · 2025Review
- Predicting Tolerance to Anthracycline Chemotherapy Using Electrocardiogram-Based Artificial Intelligence in Sarcoma.Mayo Clinic proceedings. Digital health · 2025Article
- Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment.Nature reviews. Cardiology · 2025Review
- Independent and Incremental Value of ECG Markers for Prediction of Cancer Therapy-Related Cardiac Dysfunction.Journal of the American Heart Association · 2025Article
- Applications, challenges and future directions of artificial intelligence in cardio-oncology.European journal of clinical investigation · 2025Review
- The year in cardiovascular medicine 2024: the top 10 papers in cardio-oncology.European heart journal · 2025Article
- AI and Smart Devices in Cardio-Oncology: Advancements in Cardiotoxicity Prediction and Cardiovascular Monitoring.Diagnostics (Basel, Switzerland) · 2025Review
- Artificial Intelligence Applications in Cardio-Oncology: A Comprehensive Review.Current cardiology reports · 2025Review
- A Resting ECG Screening Protocol Improved with Artificial Intelligence for the Early Detection of Cardiovascular Risk in Athletes.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
14 authors.
Funding
Abstract
aimsCardiotoxicity is a serious side effect of anthracycline treatment, most commonly manifesting as a reduction in left ventricular ejection fraction (EF). Early recognition and treatment have been advocated, but robust, convenient, and cost-effective alternatives to cardiac imaging are missing. Recent developments in artificial intelligence (AI) techniques applied to electrocardiograms (ECGs) may fill this gap, but no study so far has demonstrated its merit for the detection of an abnormal EF after anthracycline therapy. METHODS AND
resultsSingle centre consecutive cohort study of all breast cancer patients with ECG and transthoracic echocardiography (TTE) evaluation before and after (neo)adjuvant anthracycline chemotherapy. Patients with HER2-directed therapy, metastatic disease, second primary malignancy, or pre-existing cardiovascular disease were excluded from the analyses as were patients with EF decline for reasons other than anthracycline-induced cardiotoxicity. Primary readout was the diagnostic performance of AI-ECG by area under the curve (AUC) for EFs < 50%. Of 989 consecutive female breast cancer patients, 22 developed a decline in EF attributed to anthracycline therapy over a follow-up time of 9.8 ± 4.2 years. After exclusion of patients who did not have ECGs within 90 days of a TTE, 20 cases and 683 controls remained. The AI-ECG model detected an EF < 50% and ≤ 35% after anthracycline therapy with an AUC of 0.93 and 0.94, respectively.
conclusionThese data support the use of AI-ECG for cardiotoxicity screening after anthracycline-based chemotherapy. This technology could serve as a gatekeeper to more costly cardiac imaging and could enable patients to monitor themselves over long periods of time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.